Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: Data from the UK LRF CLL4 trial

Leukemia

Volumn 29, Issue 12, 2015, Pages 2411-2414

  Strefford, J C ^a   Kadalayil, L ^a   Forster, J ^a   Rose Zerilli, M J J ^a   Parker, A ^b   Lin, T T ^c   Heppel, N ^c   Norris, K ^c   Gardiner, A ^b   Davies, Z ^b   Gonzalez De Castro, D ^d   Else, M ^d   Steele, A J ^a   Parker, H ^a   Stankovic, T ^e   Pepper, C ^c   Fegan, C ^c   Baird, D ^c   Collins, A ^a   Catovsky, D ^d   Oscier, D G ^a,b   more..

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; GENETICS; HUMAN; MORTALITY; MUTATION; TELOMERE; TUMOR SUPPRESSOR GENE;

DISEASE PROGRESSION; GENES, P53; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; TELOMERE;

EID: 84951568276     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.217     Document Type: Letter

References (15)

1. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 2010; 116: 1899-1907.
2. Jones CH, Pepper C, Baird DM. Telomere dysfunction and its role in haematological cancer. Br J Haematol 2012; 156: 573-587.
3. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009; 23: 1062-1072.
4. Roos G, Kröber A, Grabowski P, Kienle D, Bühler A, Döhner H, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008; 111: 2246-2252.
5. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol 2013; 88: 647-651.
6. Grabowski P, Hultdin M, Karlsson K, Tobin G, Aleskog A, Thunberg U, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005; 105: 4807-4812.
7. Sellmann L, de Beer D, Bartels M, Opalka B, Nückel H, Dührsen U, et al. Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 2011; 93: 74-82.
8. Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S, et al. Biallelic ATM inactivation significantly reduces survival in patients treated on UK CLL4 trial. J Clin Oncol 2012; 30: 4524-4532.
9. Rose-Zerilli M, Forster J, Parker H, Parker A, Rodriguez A, Chaplin T, et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-Deleted chronic lymphocytic leukemia, data from the UK LRF CLL4 trial. Haematologica 2014; 99: 736-742.
10. Oscier DG, Rose-Zerilli MJJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 120: 4441-4443.
11. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010; 95: 1705-1712.
12. Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011; 29: 2223-2229.
13. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239.
14. Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ, et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol 2014; 167: 214-223.
15. Jebaraj BM, Busch R, Zenz T, Bühler A, Winkler D, Schnaiter A, et al. Telomere length and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2013; 122: 671.